Randomized Controlled Trial
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Jan 27, 2025; 17(1): 99327
Published online Jan 27, 2025. doi: 10.4240/wjgs.v17.i1.99327
Effect of nalbuphine on analgesia and pain factors after gastric cancer resection
Jia-Li Qian, Jie Wang, Zi-Yi Shen, Bao-Qin Xu, Dan-Ping Shen, Cheng Yang
Jia-Li Qian, Jie Wang, Zi-Yi Shen, Bao-Qin Xu, Dan-Ping Shen, Cheng Yang, Department of Anesthesiology, Suzhou Ninth People’s Hospital, Suzhou 215299, Jiangsu Province, China
Author contributions: Qian JL designed the research study; Qian JL, Wang J, Shen ZY, Xu BQ, Shen DP, and Yang C performed the research, and contributed to the new reagents and analytical tools; Qian JL and Yang C analyzed the data and wrote the manuscript; and all authors have read and approved the final manuscript.
Institutional review board statement: This study was reviewed and approved by the Institutional Review Board of Suzhou Ninth People’s Hospital, No. KYLW2024-050-01.
Clinical trial registration statement: The study was registered at the Clinical Trial Center (www.researchregistry.com) with registration number: Researchregistry10725.
Informed consent statement: All study participants and their legal guardians provided written informed consent before enrolment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Cheng Yang, Department of Anesthesiology, Suzhou Ninth People’s Hospital, No. 2666 Ludang Road, Taihu Lake New Town, Wujiang District, Suzhou 215299, Jiangsu Province, China. 17798652510@163.com
Received: September 6, 2024
Revised: September 25, 2024
Accepted: November 8, 2024
Published online: January 27, 2025
Processing time: 112 Days and 5.6 Hours
Core Tip

Core Tip: Nalbuphine, recognized for its potent analgesic properties, plays a crucial role in significantly enhancing postoperative pain management for patients who have undergone radical gastrectomy. Nalbuphine stands out due to its lower frequency of adverse reactions compared to other analgesics, which is a significant advantage in clinical settings. This lower incidence of side effects, coupled with its efficacy, positions nalbuphine as a promising candidate for improving patient recovery and overall comfort in the postoperative period, potentially leading to better patient outcomes and satisfaction.